「风雨健康之行」厉害了! O药获批胃癌+O药援助计划, “胃”来免疫治疗触手可及( 二 )


注:
*伊匹木单抗(Ipilimumab/Yervoy)尚未在中国大陆获批上市
*目前纳武利尤单抗黑色素瘤以及肝细胞癌适应症尚未在中国获批
参考文献
[1
Chen L-T. et al. A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION 2): 2 year update data [J
. Gastric Cancer 2019(19).
[2
Kang YK et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to or intolerant of at least two previous chemotherapy regimens (ONO-4538-12 ATTRACTION-2): a randomised double-blind placebo-controlled phase 3 trial. Lancet. 2017 Dec 2;390(10111):2461-2471. doi: 10.1016/S0140-6736(17)31827-5. Epub 2017 Oct 6.
[3
Chao Y et al. Nivolumab in Advanced Gastric or Gastroesophageal Junction Cancer Refractory to or Intolerant of at Least Two Previous Chemotherapy Regimens: a Taiwanese Subgroup Analysis of ATTRACTION-2 Study. Presented at the GEST (2019) Gastroenterological Society of Taiwan - 2019 Annual Meeting


推荐阅读